Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer
Advanced prostate cancers frequently develop resistance to androgen-deprivation therapy with serious implications for patient survival. Considering their importance in this type of neoplasia, epigenetic modifications have drawn attention as alternative treatment strategies. The aim of this study was...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-08-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/9/8/976 |
| _version_ | 1827685785095110656 |
|---|---|
| author | Nair Lopes Mariana Brütt Pacheco Diana Soares-Fernandes Margareta P. Correia Vânia Camilo Rui Henrique Carmen Jerónimo |
| author_facet | Nair Lopes Mariana Brütt Pacheco Diana Soares-Fernandes Margareta P. Correia Vânia Camilo Rui Henrique Carmen Jerónimo |
| author_sort | Nair Lopes |
| collection | DOAJ |
| description | Advanced prostate cancers frequently develop resistance to androgen-deprivation therapy with serious implications for patient survival. Considering their importance in this type of neoplasia, epigenetic modifications have drawn attention as alternative treatment strategies. The aim of this study was to assess the antitumoral effects of the combination of hydralazine, a DNA methylation inhibitor, with enzalutamide, an antagonist of the androgen receptor, in prostate cancer cell lines. Several biological parameters, such as cell viability, proliferation, DNA damage, and apoptosis, as well as clonogenic and invasive potential, were evaluated. The individual treatments with hydralazine and enzalutamide exerted growth-inhibitory effects in prostate cancer cells and their combined treatment displayed synergistic effects. The combination of these two drugs was very effective in decreasing malignant features of prostate cancer and may become an alternative therapeutic option for prostate cancer patient management. |
| first_indexed | 2024-03-10T08:59:22Z |
| format | Article |
| id | doaj.art-55e0e71ae26e4bc39e1795348c5018c0 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-10T08:59:22Z |
| publishDate | 2021-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-55e0e71ae26e4bc39e1795348c5018c02023-11-22T06:52:49ZengMDPI AGBiomedicines2227-90592021-08-019897610.3390/biomedicines9080976Hydralazine and Enzalutamide: Synergistic Partners against Prostate CancerNair Lopes0Mariana Brütt Pacheco1Diana Soares-Fernandes2Margareta P. Correia3Vânia Camilo4Rui Henrique5Carmen Jerónimo6Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, PortugalCancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, PortugalCancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, PortugalCancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, PortugalCancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, PortugalCancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, PortugalCancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, PortugalAdvanced prostate cancers frequently develop resistance to androgen-deprivation therapy with serious implications for patient survival. Considering their importance in this type of neoplasia, epigenetic modifications have drawn attention as alternative treatment strategies. The aim of this study was to assess the antitumoral effects of the combination of hydralazine, a DNA methylation inhibitor, with enzalutamide, an antagonist of the androgen receptor, in prostate cancer cell lines. Several biological parameters, such as cell viability, proliferation, DNA damage, and apoptosis, as well as clonogenic and invasive potential, were evaluated. The individual treatments with hydralazine and enzalutamide exerted growth-inhibitory effects in prostate cancer cells and their combined treatment displayed synergistic effects. The combination of these two drugs was very effective in decreasing malignant features of prostate cancer and may become an alternative therapeutic option for prostate cancer patient management.https://www.mdpi.com/2227-9059/9/8/976hydralazineenzalutamidecastration-resistant prostate cancerepigenetics |
| spellingShingle | Nair Lopes Mariana Brütt Pacheco Diana Soares-Fernandes Margareta P. Correia Vânia Camilo Rui Henrique Carmen Jerónimo Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer Biomedicines hydralazine enzalutamide castration-resistant prostate cancer epigenetics |
| title | Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer |
| title_full | Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer |
| title_fullStr | Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer |
| title_full_unstemmed | Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer |
| title_short | Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer |
| title_sort | hydralazine and enzalutamide synergistic partners against prostate cancer |
| topic | hydralazine enzalutamide castration-resistant prostate cancer epigenetics |
| url | https://www.mdpi.com/2227-9059/9/8/976 |
| work_keys_str_mv | AT nairlopes hydralazineandenzalutamidesynergisticpartnersagainstprostatecancer AT marianabruttpacheco hydralazineandenzalutamidesynergisticpartnersagainstprostatecancer AT dianasoaresfernandes hydralazineandenzalutamidesynergisticpartnersagainstprostatecancer AT margaretapcorreia hydralazineandenzalutamidesynergisticpartnersagainstprostatecancer AT vaniacamilo hydralazineandenzalutamidesynergisticpartnersagainstprostatecancer AT ruihenrique hydralazineandenzalutamidesynergisticpartnersagainstprostatecancer AT carmenjeronimo hydralazineandenzalutamidesynergisticpartnersagainstprostatecancer |